Very few reports have been published in Latin America about cytomegalovirus infection and disease in bone marrow transplant (BMT) patients. In spite of the economic, political and social difficulties, such patients deserve an appropriate and opportune treatment for their illness. With limited resources, it has been possible to establish programs of hematopoietic transplants that have given good results. 1 Even so, the prevalence of infection for cytomegalovirus (CMV) in those patients is a problem, since prompt diagnosis is necessary to minimize morbidity and mortality. The antigenemia pp65 assay for CMV is a quick and economic test to detect the reactive infection for CMV. 2 This report describes our experience with the antigenemia test for the diagnosis of CMV infection in our BMT unit at the Hospital Universitario San Vicente de Paul, University of Antioquia, Medellı´n, Colombia.
Between January 2000 and December 2001, 211 peripheral blood samples were processed for detection of CMV antigen pp65 using the antigenemia test (CMV Brite, IQ corporation, Groningen, The Netherlands). These samples were obtained from 19 allo-transplanted patients (17 PBSC, one bone marrow and one unrelated UCB). We reviewed demographic data, clinical evolution and treatment for each patient from clinical records. All donors and recipients had pretransplant CMV positive serology ( Table 1 ). The management protocol for hematopoietic transplant recipients in our hospital includes a weekly antigenemia test during the first 100 days posttransplant and at any time thereafter the physician considered necessary.
Diagnosis of graft-versus-host disease (GVHD) was suggested when patients exhibited characteristic symptoms such as diarrhea, dermatitis or jaundice and the disease was confirmed with skin or intestinal biopsy.
Transplant recipients received irradiated and filtered blood products and acyclovir prophylactically at a dose of 1500 mg/m 2 /day during the first 100 days. If antigenemia assays were positive, treatment with intravenous ganciclovir was started at a dose of 5 mg/kg every 12 h for 3-4 weeks. The suppressive therapy continued at 2.5 mg/kg every 12 h until day 100 post-transplant.
Positive antigenemia was detected in 37 samples (17%) with nine of 19 patients (48%) developing positive CMV antigenemia. The median time to the first detection of positive CMV antigenemia was 48 days post-transplant (range: 17-194 days). The median number of positive cells found in positive antigenemia patients was 1.73 cells (range: 1 at 50 per 1.5 Â 10 5 leukocytes). None of the patients, either with positive or negative antigenemia, presented with CMV disease. The inter-relations between positive antigenemia, GVHD and mortality rate was investigated by bivariate analysis. Significant association was only found between positive antigenemia and GVHD (P ¼ 0.003). The results of this report show that even without advanced technology, it is possible to carry out appropriate management of patients with BMT.
During the last decade, several studies have shown the benefits of following up an immunocompromised host with CMV antigenemia. Mori et al 3 demonstrated that antigenemia for HCMV is a good indicator for starting preemptive therapy with ganciclovir in patients with bone marrow transplantation. In that study, 44% of patients developed positive antigenemia for CMV, with a median detection interval of the first antigenemia of 38.2 days and with a statistically significant association with GVHD. They concluded that pre-emptive therapy based upon CMV antigenemia could effectively prevent the occurrence of CMV pneumonia and CMV-related mortality. Schulenburg et al 4 reported a lower incidence of CMV-related diseases using pre-emptive therapy with gancyclovir and a high risk of CMV infection in patients with GVHD. Consistent with reported results, none of the patients with positive antigenemia who received suppressive antiviral therapy with gancyclovir in our study exhibited CMV disease associated with activation of CMV 5 . Although the study was carried out with a limited number of patients, the results clearly demonstrated the feasibility and utility of the 
